

1 **BEFORE THE ARIZONA REGULATORY BOARD**
2 **OF PHYSICIAN ASSISTANTS**

3 In the Matter of:

4 **ERIK B. C. BUZAN, P.A.**

5 Holder of License No. 5148
6 For the Performance of Healthcare
7 Tasks
8 In the State of Arizona

9 *Respondent.*

Case No. PA-22-0053A

**FINDINGS OF FACT,
CONCLUSIONS OF LAW AND
ORDER FOR LETTER OF
REPRIMAND AND PROBATION;
AND CONSENT TO SAME**

10 The Arizona Regulatory Board of Physician Assistants (“Board”) considered
11 this matter at its public meeting on February 28, 2024. Erik B. C. Buzan, P.A.
12 (“Respondent”), appeared before the Board for a Formal Interview pursuant to the
13 authority vested in the Board by A.R.S. § 32-2551(G). The Board voted to issue
14 Findings of Fact, Conclusions of Law and Order after due consideration of the facts
15 and law applicable to this matter.

16 **FINDINGS OF FACT**

17 1. The Board is the duly constituted authority for the regulation and
18 control of physician assistants in the State of Arizona.

19 2. Respondent is the holder of license number 5148 for the performance
20 of health care tasks in the State of Arizona.

21 3. The Board initiated case number PA-22-0053A after receiving a
22 complaint regarding Respondent’s care and treatment care and treatment of a 33
23 year-old male patient (“VF”) alleging inappropriate prescribing of controlled
24 substances. Based on the complaint, Board staff requested Medical Consultant
25 (“MC”) review of Respondent’s care and treatment of VF.

26 4. On September 4, 2020, VF established care with Respondent for
27 primary care and pain management. VF had a history of musculoskeletal injuries

1 from an ATV accident requiring approximately 20 surgeries with multiple
2 complications. VF reported using medical marijuana and alcohol. Respondent
3 prescribed oxycodone 15mg every 6 hours #120.

4 5. On October 2, 2020, VF requested testosterone hormone therapy to
5 assist with bone healing. VF's serum testosterone level was 271 ng/dl. Respondent
6 prescribed testosterone cypionate and Arimidex 1mg weekly. Respondent
7 increased VF's oxycodone 15mg every 4-6 hours #150.

8 6. Respondent continued to treat VF through July 2022, and prescribed
9 VF medications including Trazodone, Xanax, testosterone, zaleplon and
10 oxycodone. On May 3, 2021, a note was added to VF's medical record that
11 narcotic doses would not be increased and the patient needed to be referred to
12 pain management.

13 7. On May 23, 2022, VF requested Adderall because he was having
14 surgery to have the rod in his leg removed and would be required to work at his
15 desk for 3-6 months. VF reported that his current prescription for zolpidem was
16 working for sleep and requested that Xanax be stopped. Respondent prescribed
17 Adderall 30mg daily and discontinued Xanax.

18 8. On July 19, 2022, VF reported being involved in a motorcycle accident
19 resulting in a compound leg fracture on June 27, 2022. Respondent added
20 gabapentin 600mg three times daily. VF was informed that this would be his last
21 appointment and VF was referred for pain management.

22 9. The standard of care prohibits a physician assistant from prescribing
23 high dose opioids without clinical justification. Respondent deviated from this
24 standard of care by prescribing high dose opioids without clinical justification.

25 10. The standard of care prohibits a physician assistant from prescribing a
26 combination of high dose opioids and benzodiazepines without clinical justification.

27

1 Respondent deviated from the standard of care by prescribing a combination of
2 high dose opioids and benzodiazepines without clinical justification.

3 11. The standard of care prohibits a physician assistant from prescribing
4 Adderall without clinical justification. Respondent deviated from the standard of
5 care by prescribing Adderall without clinical justification.

6 12. The standard of care requires a physician assistant to prescribe
7 Narcan to patients on high dose opioids. Respondent deviated from the standard
8 of care by failing to prescribe Narcan to a patient on high dose opioids.

9 13. The standard of care requires a physician assistant to prescribe
10 testosterone at a therapeutic level. Respondent deviated from the standard of care
11 by prescribing testosterone at a higher than recommended physiological range.

12 14. There was actual patient harm in that the patient became opioid
13 dependent.

14 15. There was the potential for patient harm in that the patient was at risk
15 for opioid addiction, respiratory depression, overdose and death. In addition, the
16 patient was at risk of cardiovascular disease due to uncontrolled hyperlipidemia.
17 Lastly, the patient was at risk of mood swings, aggressive behavior, heart muscle
18 damage, insomnia, and prostate enlargement from the testosterone treatment.

19 16. Effective December 22, 2023, Respondent entered into an Interim
20 Consent for Practice Restriction prohibiting him from prescribing controlled
21 substances.

22 17. On January 6-7, 2024, Respondent completed a Board-staff pre-
23 approved intensive virtual Continuing Medical Education ("CME") course in
24 controlled substance prescribing for 21 CME credit hours.

25 18. On January 10, 2024, Respondent completed a Board staff pre-
26 approved intensive virtual CME course in medical recordkeeping for 10.5 CME
27 credit hours.

1 19. On February 1, 2024, the Interim Consent Agreement for Practice
2 Restriction was terminated based on Respondent's completion of CME.

3 20. On February 27, 2024, Respondent submitted an additional licensee
4 response stating that after completing the CME he met with his office staff to make
5 changes recommended during his educational courses regarding documentation,
6 abuse screening and mental health concerns. Respondent additionally submitted a
7 copy of his certificate of completion of an intensive, in-person CME course in
8 controlled substance prescribing for 21 CME credit hours completed pursuant to a
9 Non-Disciplinary Continuing Medical Education Order in PA-17-0046A.

10 21. During the Formal Interview on the matter, Respondent stated that the
11 case with VF was very difficult. Respondent stated that after graduating from PA
12 school in 2012, he began working for an internal medicine practice. Respondent
13 stated that he worked with several different practitioners, but that his first
14 Supervising Physician ("SP") often saw high dose pain management patients and
15 that Respondent would see the patients the SP was unable to see. Respondent
16 stated he saw an increasing amount of pain management patients, and that he did
17 not have much control over his patient population until 2021 when a new Medical
18 Director ("SP2") came to the practice. Respondent stated that since that time,
19 many changes occurred in the practice including testosterone prescribing protocols,
20 ADHD protocols, and referring out patients who were receiving more than 90
21 morphine milligram equivalents ("MME") of opioid medications. Respondent noted
22 that VF was one of the patients referred to pain management for medication
23 management. Respondent stated that he learned from the CME, cooperated with
24 the Board's investigation process and incorporated the education into his practice in
25 order to provide better quality of care to his patients. Respondent also stated that
26 he has ceased taking pain management patients. Respondent requested that the
27

1 Board not require him to undergo chart reviews and issue an advisory letter based
2 on the remediation already completed.

3 22. Respondent testified regarding his care and treatment of VF.
4 Respondent stated that his initial treatment of VF conformed with his training and
5 experience as a young medical professional. Respondent stated that with regard to
6 benzodiazepine prescriptions, he did have a discussion with VF regarding the
7 indications for the prescriptions, but did not document it. Respondent testified
8 regarding changes to his practice, for both controlled substance prescribing,
9 testosterone therapy and for primary care services.

10 23. When asked about why he had failed to incorporate the education from
11 the 2018 controlled substance prescribing course into his practice, Respondent
12 stated that his supervising physician did not implement protocols or limit controlled
13 substance prescribing, and his patient population did not change. Respondent
14 further stated that in his opinion, there was never any guidance by an SP until SP2
15 joined the practice as medical director. Respondent stated that SP2 implemented
16 more communication, documentation, protocols and policy restrictions than were
17 previously in place at the practice. Respondent stated that he believes that VF's
18 care would have been different if the changes had occurred sooner. Respondent
19 accepted responsibility for not incorporating the education into his practice on his
20 own. Respondent stated that the medical recordkeeping course taught him about
21 what he needed to put on paper regarding his medical records.

22 24. Also, during the Formal Interview, Board members expressed concern
23 regarding Respondent's attempts to cite the SP's lack of formalized policies as the
24 basis for deficiencies in VF's care and Respondent's documentation. Board
25 members agreed that the matter rose to the level of discipline, and voted to issue
26 Respondent an order for Letter of Reprimand and Probation with a requirement to
27 undergo periodic chart reviews.

1 **CONCLUSIONS OF LAW**

2 1. The Board possesses jurisdiction over the subject matter hereof and
3 over Respondent.

4 2. The conduct and circumstances described above constitute
5 unprofessional conduct pursuant to A.R.S. § 32-2501(20)(j) (“Committing any
6 conduct or practice that is or might be harmful or dangerous to the health of a
7 patient or the public.”).

8 3. The conduct and circumstances described above constitute
9 unprofessional conduct pursuant to A.R.S. § 32-2501(20)(p) (“Failing or refusing to
10 maintain adequate records for a patient.”).

11 **ORDER**

12 IT IS HEREBY ORDERED THAT:

13 1. Respondent is issued a Letter of Reprimand;

14 2. Respondent is placed on Probation for a period of two years with the
15 following terms and conditions:

16 a. **Chart Reviews**

17 Within 30 days of the effective date of this Order, Respondent shall enter into
18 a contract with a Board-approved monitoring company to perform periodic chart
19 reviews at Respondent’s expense. The chart reviews shall involve current patients’
20 charts for care rendered after February 1, 2024. Based upon the chart review, the
21 Board retains jurisdiction to take additional disciplinary or remedial action.

22 b. **Probation Termination**

23 After three consecutive favorable chart reviews, Respondent may petition the
24 Board to terminate the Probation. Respondent may not request early termination
25 without satisfaction of the chart review requirements as stated in this Order.

26
27

1 The Probation shall not terminate except upon affirmative request of
2 Respondent and approval by the Board.

3 Prior to any Board consideration for termination of Probation, Respondent
4 must submit a written request to the Board for release from the terms of this Order.
5 Respondent's request for release will be placed on the next pending Board agenda,
6 provided a complete submission is received by Board staff no less than 30 days
7 prior to the Board meeting. Respondent's request for release must provide the
8 Board with evidence establishing that he has successfully satisfied all of the terms
9 and conditions of this Order.

10 The Board has the sole discretion to determine whether all of the terms and
11 conditions of this Order have been met or whether to take any other action that is
12 consistent with its statutory and regulatory authority.

13 **c. Obey All Laws**

14 Respondent shall obey all state, federal and local laws, and all rules
15 governing the performance of healthcare tasks in Arizona.

16 3. The Board retains jurisdiction and may initiate new action against
17 Respondent based upon any violation of this Order. A.R.S. § 32-2501(20)(ee).

18 **RIGHT TO PETITION FOR REHEARING OR REVIEW**

19 Respondent is hereby notified that he has the right to petition for a rehearing
20 or review. The petition for rehearing or review must be filed with the board's
21 executive director within thirty (30) days after service of this order. A.R.S. § 41-
22 1092.09(B). The petition for rehearing or review must set forth legally sufficient
23 reasons for granting a rehearing or review. A.A.C. R4-16-103. Service of this order
24 is effective five (5) days after date of mailing. A.R.S. § 41-1092.09(C). If a petition
25 for rehearing or review is not filed, the board's order becomes effective thirty-five
26 (35) days after it is mailed to respondent.
27

1 Respondent is further notified that the filing of a motion for rehearing or
2 review is required to preserve any rights of appeal to the superior court.

3
4 DATED AND EFFECTIVE this 29th day of May, 2024.

5
6 ARIZONA REGULATORY BOARD
7 OF PHYSICIAN ASSISTANTS

8 By Pat E. McSorley
9 Patricia E. McSorley
10 Executive Director

11
12 **EXECUTED COPY** of the foregoing mailed
13 this 29th day of May, 2024 to:

14 Erik B. C. Buzan, P.A.
15 Address of Record

16
17 **ORIGINAL** of the foregoing filed
18 this 29th day of May, 2024 with:

19 Arizona Regulatory Board
20 of Physician Assistants
21 1740 West Adams, Suite 4000
22 Phoenix, Arizona 85007

23 Michelle Kubus
24 Board staff